Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on AmpliPhi Biosciences Corporation


Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

AmpliPhi Biosciences, (formerly known as Targeted Genetics Corporation), develops gene-based products for the treatment of acquired and inherited diseases. It raised $9.1 million in a secondary public offering, as reported in the PharmSource Lead Sheet on May 11, 2017.

Corporate Highlights

  • AmpliPhi Biosciences was incorporated in Washington in March 1989 as a subsidiary of Immunex Corporation, began operations in 1992 and changed its name to AmpliPhi Biosciences in February 2011.
  • Corporate Headquarters: San Diego, CA – approximately 1,000 square feet of office space
  • Other facilities: Richmond, VA; Brookvale, Australia; Ljubljana, Slovenia
  • Stock Exchange: NYSE
  • Stock Symbol: APHB

Sourcing Opportunities

  • AmpliPhi Biosciences plans to use the proceeds to fund general corporate purposes, including manufacturing, R&D activities and ongoing clinical trials of its pipeline, which may include:
    • AB-PA01 – To complete preclinical studies:
      • For treatment of Pseudomonas aeruginosa lung infections in Cystic Fibrosis (CF) patients
      • Dosage Form: Intranasal; Topical; Inhaled
      • Nature of API: Biologic – Genetically modified virus
      • Therapeutic Areas: Antibacterial; Pulmonary
  • AB-SA01 – To complete a Phase I study:
    • For treatment of Staphylococcus aureus infections
    • Dosage Form: Topical; Semi-solid – Non-sterile
    • Nature of API: Biologic – Unspecified
    • Therapeutic Areas: Antibacterial
  • The company contracts with contract research organizations (CROs) to conduct clinical trials.
  • AmpliPhi Biosciences owns and operates a manufacturing facility in Ljubljana, Slovenia for all required raw materials, API and finished product for preclinical studies and clinical trials through initial Phase III trials.
  • AmpliPhi Biosciences has no sales, marketing and distribution capabilities.
  • Business Relationships

    • In September 2015, AmpliPhi Biosciences and Takara Bio entered into a patent license agreement where Takara Bio received certain patents related to AAV1 Vector gene delivery systems. AmpliPhi Biosciences received a $40,000 up-front payment and up to $85,000 in royalty and milestone payments.
    • In June 2013, AmpliPhi Biosciences and the US Army Medical Research and Materiel Command entered into an agreement for the research and development of bacteriophage therapeutics to treat S. aureus infections. Financial terms were undisclosed.1

    Drug Product Pipeline

    Product Candidate Indication Dosage Form Status Next Anticipated Step
    AB-PA01 Pseudomonas aeruginosa lung infections in Cystic Fibrosis (CF) patients Intranasal; Topical; Inhaled Preclinical TBA
    AB-PA01 Pseudomonas aeruginosa lung infections in chronic rhinosinusitis Intranasal; Topical; Inhaled Preclinical TBA
    AB-SA01 Staphylococcus aureus infections Topical; Semi-solid – Non-sterile Phase I Initiate a Phase II study in 2017
    AB-SA01 Chronic rhinosinusitis associated with Staphylococcus aureus infection Intranasal; Topical Phase I TBA


    (In $ thousands) 2016 2015
    R&D Expenditures
    General & Administrative Expenditures
    Total Operating Expenses

    1AmpliPhi Biosciences Corporation, 3/27/17 10-K,

    Contact Information

    AmpliPhi Biosciences Corporation Key Officers
    3579 Valley Centre Drive, Suite 100 M. Scott Salka, CEO
    San Diego, CA, 92130 USA Barbara Hubad, Manager, Quality Control
    Phone: +1-858-829-0829 Sandra Morales, Global Head, Research
    Web: Francisco Rosas, Associate Director, Regulatory Affairs

    Related posts:
    Follow the Money to Pharmaceutical Opportunities – Spotlight on ContraVir Pharmaceuticals, Inc.
    Follow the Money to Pharmaceutical Opportunities – Spotlight on BioCryst Pharmaceuticals, Inc.
    Follow the Money to Pharmaceutical Opportunities – Spotlight on Aldeyra Therapeutics, Inc.

    Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

    More posts by Scotty Chung-Siu